- Conditions
- Post-menopausal Vasomotor Symptoms
- Interventions
- ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID, Placebo
- Drug
- Lead sponsor
- Acer Therapeutics Inc.
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vascular Ehlers-Danlos Syndrome
- Interventions
- ACER-002 (celiprolol) 200 mg BID, Placebo BID
- Drug
- Lead sponsor
- Acer Therapeutics Inc.
- Industry
- Eligibility
- 15 Years to 64 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Culver City, California
- Conditions
- Medium-chain Acyl-CoA Dehydrogenase Deficiency
- Interventions
- Sodium phenylbutyrate
- Drug
- Lead sponsor
- Jerry Vockley, MD, PhD
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania